Close×

Tetra Pak has created a marketing opportunity which allows beverage companies to turn their drinks into ice creams and frozen products.

The Tetra Fino Aseptic 100 Ultra MiM package gives customers the opportunity to produce liquid dairy and juice drinks using their existing production processes and then market them as ice creams.

Dairy and juice drinks can be produced and distributed in small carton pouches at room temperature, then turned into frozen products in shops or in a consumer’s home.

This allows producers to tap into the $72 billion global ice cream market without the need for additional investment in production equipment and chilled distribution systems.

Tpak2.jpg

Want Want, a leading food company in China, was the first company to trial the product with its preservative-free flavoured milk.

It announced the new products to distributors in early September, and the response has been positive as it appeals to both  parents and children.

The Tetra Fino Aseptic 100 Ultra MiM package can be produced on the A1 Tetra Pak filling machine platform.

With a pre-applied opening using Micro Injection Moulding technology, the package can be opened entirely by pulling the tab, making it easy for children and others to enjoy.

The new package will initially be available from 2018 in the Greater Middle East, Europe and Asia.

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.